In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination treatment of avutometinib and defactinib for a rare form of ovarian cancer. | ...

Even as Roche makes a major investment pledge across its U.S. business, the Swiss pharmaceutical giant isn’t neglecting its ...

Angela Hwang spent nearly three decades at Pfizer before joining Flagship Pioneering in 2025 as a CEO-partner and the CEO of ...

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

The drug also reduced the risk of death by 25% in that study, representing the first PD-1/L1 inhibitor to deliver a survival win for MIBC patients. Meanwhile, Pfizer recently tested its ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

In the wake of mass restructuring efforts across the Department of Health and Human Services (HHS), the FDA has missed yet ...

During his first term, attempts by President Donald Trump to slash drug price | After failing in his first term to install a most favored nation plan to reduce drug prices, President Donald Trump is ...